Corestemchemon Inc
166480
Company Profile
Business description
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.
Contact
Pangyo 255 beongil 24 I & C Building, 2nd Floor
yeonggi-do, Bundang-gu
Seongnam
Seoul13486
KORT: +82 24973711
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
326
Stocks News & Analysis
stocks
Our view after CBA shares plunge
Steady profit, but rising risks and rich valuation give pause.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,884.70 | 18.30 | 0.21% |
| CAC 40 | 8,082.27 | 0.00 | 0.00% |
| DAX 40 | 24,456.26 | 319.45 | 1.32% |
| Dow JONES (US) | 50,048.26 | 355.06 | 0.71% |
| FTSE 100 | 10,372.93 | 47.58 | 0.46% |
| HKSE | 26,389.04 | 0.60 | 0.00% |
| NASDAQ | 26,601.89 | 199.54 | 0.76% |
| Nikkei 225 | 62,654.05 | 618.06 | -0.98% |
| NZX 50 Index | 13,025.07 | 37.99 | -0.29% |
| S&P 500 | 7,493.78 | 49.53 | 0.67% |
| S&P/ASX 200 | 8,640.70 | 26.00 | 0.30% |
| SSE Composite Index | 4,177.92 | 64.65 | -1.52% |